ICON PUBLIC LIMITED COMPANY

ICON plc is a global leader in clinical research and development services, helping biopharma, medical-device and health-technology companies bring innovative therapies to market. Drawing on deep scientific expertise and cutting-edge technology, ICON offers end-to-end solutions that span early-phase clinical and bioanalytical work, site and patient recruitment, cardiac safety monitoring, specialty laboratory support and market-access strategy.

The company's portfolio includes AI-enhanced platforms such as EngageAI for real-time voice-of-customer feedback, bespoke blended solutions tailored to sponsor challenges, and Outcome Measures that focus on evidence-based, patient-centred endpoints. ICON also provides dedicated biotech services-due-diligence, asset valuation and flexible outsourcing-plus comprehensive cardiac safety studies, real-world data integration, and tokenisation for vaccine follow-up. Its thought-leadership is showcased through regular whitepapers, webinars and insights on topics ranging from neurodegenerative trial design to AI in software-as-a-medical-device (SaMD).

With a reputation for pragmatic, award-winning innovation, ICON partners with organisations worldwide to accelerate drug and device development, reduce risk and ultimately improve patient outcomes.